

## SUMMARY

### Offer Price

- The Offer Price has been determined at HK\$30.50 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%).

### Net Proceeds from the Global Offering

- The net proceeds from the Global Offering, after deducting the underwriting fees and other estimated expenses paid and payable by us in connection with the Global Offering and taking into account any additional discretionary incentive fee (assuming the full payment of the discretionary incentive fee), assuming that the Over-allotment Option is not exercised, are estimated to be approximately HK\$481.7 million, based on the Offer Price of HK\$30.50 per Offer Share. We intend to apply such net proceeds in accordance with the purposes set out in the section headed “Net Proceeds from the Global Offering” in this announcement.
- If the Over-allotment Option is exercised in full, we will receive additional net proceeds of approximately HK\$83.4 million for 2,850,000 Offer Shares to be issued upon the exercise of the Over-allotment Option.

### Applications and Indications of Interest Received in the Hong Kong Public Offering

- The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been slightly over-subscribed. A total of 8,629 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 14,988,500 Offer Shares, representing approximately 7.89 times of the total number of 1,900,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the over-subscription in the Hong Kong Public Offering represents less than 15 times of the number of the Offer Shares initially available for subscription under the Hong Kong Public Offering, no reallocation procedures as described in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus has been applied. The final number of Offer Shares under the Hong Kong Public Offering is 1,900,000 Offer Shares, representing 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 5,793 successful applicants under the Hong Kong Public Offering. A total number of 4,262 applicants have been allotted with one board lot of Offer Shares.

## **International Offering**

- The Offer Shares initially offered under the International Offering were slightly over-subscribed, representing approximately 2.15 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares allocated to the placees under the International Offering is 17,100,000 Shares, representing 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total of 194 placees under the International Offering. A total of 139 placees have been allotted five board lots of Offer Shares or less, representing approximately 71.6% of 194 placees under the International Offering. These placees have been allotted 18,600 Shares in total, representing approximately 0.1 % of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

## **Cornerstone Investors**

- Pursuant to the Cornerstone Investment Agreements with the Cornerstone Investors, the number of Offer Shares subscribed for by the Cornerstone Investors has now been determined. Sanofi Foreign Participations B.V. has subscribed for 3,860,600 Offer Shares, Harvest International Premium Value (Secondary Market) Fund SPC on behalf of Harvest Great Bay Investment SP has subscribed for 5,147,500 Offer Shares, Yangtze River (Hong Kong) Limited has subscribed for 1,286,800 Offer Shares and Tasly International Capital Limited has subscribed for 1,286,800 Offer Shares, in all totaling 11,581,700 Offer Shares, representing approximately (i) 60.96% of the Offer Shares initially available under the Global Offering (assuming that the Over-allotment Option is not exercised); and (ii) 1.97% of the total issued share capital of the Company immediately following the completion of the Global Offering (assuming that the Over-allotment Option is not exercised and excluding shares to be issued under the Share Incentive Plans). Please refer to the section headed “Cornerstone Placing” in the Prospectus for further details relating to the Cornerstone Investors.
- We have applied to the Stock Exchange for, and the Stock Exchange has granted us, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and consent under paragraph 5(2) of Appendix 6 to the Listing Rules to allow the Relevant Cornerstone Investor to participate in the Global Offering as a cornerstone investor.

## **Placings of Offer Shares to a close associate of an existing shareholder with consent under paragraph 5(2) of the Placing Guidelines**

- We have applied to the Stock Exchange for, and the Stock Exchange has granted us, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and consent under paragraph 5(2) of Appendix 6 to the Placing Guidelines to permit the Company to allocate Offer Shares in the Global Offering to Xie Xiaomei (謝曉梅), a close associate of an existing shareholder, as set out in the section headed “International Offering — Placings of Offer Shares to a close associate of an existing shareholder with consent under paragraph 5(2) of the Placing Guidelines” as places under the International Offering.

## **Over-allotment Option**

- In connection with the Global Offering, we have granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives (for themselves and on behalf of the International Underwriters), at any time from the Listing Date until Thursday, July 28, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require us to allot and issue up to an aggregate of 2,850,000 additional Offer Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price, to cover the over-allocations in the International Offering. There has been an over-allocation of 2,850,000 Offer Shares in the International Offering and such over-allocation will be settled using Shares to be borrowed under the Stock Borrowing Agreement between Morgan Stanley Asia Limited and HaoYuan health Limited. Such borrowed Shares will be covered by, among other methods, exercising the Over-allotment Option in full or in part or by using Shares purchased by the Stabilizing Manager (or through its affiliates or any person acting for it) in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on our website and the website of the Stock Exchange at [www.cloudr.cn](http://www.cloudr.cn) and [www.hkexnews.hk](http://www.hkexnews.hk), respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

## **Lock-up Undertakings**

- The Company, almost all existing Shareholders and the Cornerstone Investors are subject to certain lock-up undertakings as set out in the section headed “Lock-up Undertakings” in this announcement.

## Results of Allocation

- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **HK eIPO White Form** service or through the **CCASS EIPO** service, including the Hong Kong identity card numbers, passport numbers, Hong Kong business registration numbers or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares, successfully applied for, will be made available at the times and dates and in the manner specified below:
  - (i) in the announcement to be posted on our website and the website of the Stock Exchange at [www.cloudr.cn](http://www.cloudr.cn) and [www.hkexnews.hk](http://www.hkexnews.hk), respectively, by no later than Tuesday, July 5, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
  - (ii) from the “IPO Results” function in the **IPO App** or the designated results of allocations website at [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) or [www.tricor.com.hk/ipo/result](http://www.tricor.com.hk/ipo/result) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Tuesday, July 5, 2022 to 12:00 midnight on Monday, July 11, 2022; and
  - (iii) from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Tuesday, July 5, 2022 to Friday, July 8, 2022.
- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

- Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

#### **Dispatch/Collection of Share Certificates/e-Auto Refund Payment Instructions/Refund Checks**

- Applicants who applied for 500,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service and who have been successfully or partially successfully allocated Hong Kong Offer Shares and are eligible to collect Share certificates in person may collect Share certificates from the Hong Kong Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on, Tuesday, July 5, 2022, or any other place or date we may notify. Share certificates for Hong Kong Offer Shares allocated to applicants who applied through the **HK eIPO White Form** service which are either not available for personal collection or which are available but are not collected in person by 1:00 p.m. on Tuesday, July 5, 2022, are expected to be dispatched by ordinary post to the addresses specified in the relevant applications at their own risk.
- Applicants being individuals who are eligible for personal collection cannot authorize any other person to make collection on their behalf. Corporate applicants which are eligible for personal collection must attend by their authorised representatives bearing letters of authorisation from their corporations stamped with the corporations’ chops. Both individuals and authorised representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Tricor Investor Services Limited.
- Share certificates for Hong Kong Offer Shares allotted to applicants who applied for less than 500,000 Hong Kong Offer Shares through the **HK eIPO White Form** service are expected to be despatched to those entitled to the addresses specified in the relevant application instructions by ordinary post at their own risk on or before Tuesday, July 5, 2022.

- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their Share certificates issued in the name of HKSCC Nominees and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave **electronic application instructions** on their behalf on Tuesday, July 5, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies payable to them with that CCASS Participant.
- Applicants who applied through the **HK eIPO White Form** service and paid the application monies from a single bank account will have refund monies (if any) dispatched to their application payment account in the form of e-Auto Refund payment instructions on Tuesday, July 5, 2022. Applicants who applied through the **HK eIPO White Form** service and paid the application monies from multiple bank accounts will have refund monies (if any) dispatched to the addresses specified on their **HK eIPO White Form** applications in the form of refund check(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant), by ordinary post at their own risk on or before Tuesday, July 5, 2022.
- Refund monies for applicants who have applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to their designated bank accounts or the designated bank accounts of their brokers or custodians on Tuesday, July 5, 2022.
- Share certificates will only become valid at 8:00 a.m. on Wednesday, July 6, 2022 provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination described in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised.
- We will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

## **Public Float**

- The Directors confirm that:
  - (i) immediately after completion of the Global Offering, assuming the Over-Allotment Option is not exercised and no Shares will be allotted and issued under the Share Incentive Schemes, the number of Shares in the public hands represents no less than 25% of the total issued share capital of the Company, and that there will not be any new substantial Shareholder immediately after the Global Offering within the meaning of the Listing Rules and the number of Shares to be held by the public satisfies the minimum percentage prescribed in Rule 8.08(1) of the Listing Rules;
  - (ii) the Share will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule 8.08(2) of the Listing Rules; and
  - (iii) the three largest public Shareholders will not hold more than 50% of the Shares held in public hands at the time of Listing, in compliance with Rule 8.08(3) of the Listing Rules.

## **Commencement of Dealings**

- Dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, July 6, 2022. Shares will be traded in board lots of 100 Shares each. The stock code of the Shares is 9955.

## **OFFER PRICE**

The Offer Price has been determined at HK\$30.50 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%).

## NET PROCEEDS FROM THE GLOBAL OFFERING

The net proceeds from the Global Offering, after deducting the underwriting fees and other estimated expenses paid and payable by us in connection with the Global Offering and taking into account any additional discretionary incentive fee (assuming the full payment of the discretionary incentive fee), assuming that the Over-allotment Option is not exercised and no Shares are issued under the Share Incentive Schemes, are estimated to be approximately HK\$481.7 million, based on the Offer Price of HK\$30.50 per Offer Share.

We intend to apply such net proceeds for the following purposes:

- (i) approximately 60% of the net proceeds is expected to be used for business expansion, we will continue to pursue the “hospital-first” strategy and expand our hospital network nationwide. Leveraging our hospital network, we will also continue to connect with more industry participants along the industry value chain and continue to enhance and expand our solution offering to drive customer and user engagement;
- (ii) approximately 25% of the net proceeds is expected to be used to advance our medical know-how and technology capabilities to reinforce our leadership in the digital healthcare industry, which will allow us to deepen our connections with industry participants and deliver better medical treatment;
- (iii) approximately 5% of the net proceeds is expected to be used to broaden our ecosystem through strategic partnerships, investments and acquisitions in other businesses that complement our organic growth strategies. We plan to continue to elevate our presence in the upstream and downstream of value chain and selectively pursue alliance and investment opportunities; and
- (iv) approximately 10% of the net proceeds is expected to be used for working capital and generate corporate purposes.

If the Over-allotment Option is exercised in full, we will receive additional net proceeds of approximately HK\$83.4 million for 2,850,000 additional Offer Shares to be issued upon the exercise of the Over-allotment Option.

For further information, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.



Morgan Stanley Asia Limited and J.P. Morgan Securities (Far East) Limited are the Joint Sponsors. Morgan Stanley Asia Limited, J.P. Morgan Securities (Asia Pacific) Limited, China International Capital Corporation Hong Kong Securities Limited and CMB International Capital Limited are the Joint Global Coordinators. Together with the Joint Global Coordinators, J.P. Morgan Securities plc and Valuable Capital Limited are the Joint Bookrunners (the “**Joint Bookrunners**”).

## **APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED IN THE HONG KONG PUBLIC OFFERING**

The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been slightly over-subscribed. A total of 8,629 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 14,988,500 Offer Shares, representing approximately 7.89 times of the total number of 1,900,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 8,611 valid applications in respect of a total of 6,638,500 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$30.50 per Hong Kong Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) of HK\$5 million or less, representing approximately 6.99 times of the 950,000 Hong Kong Offer Shares initially comprised in pool A; and
- 18 valid applications in respect of a total of 8,350,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$30.50 per Hong Kong Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) of more than HK\$5 million, representing approximately 8.79 times of the 950,000 Hong Kong Offer Shares initially comprised in pool B.

6 multiple or suspected multiple applications have been identified and rejected. No dishonored payments has been identified and rejected. No application for more than 950,000 Hong Kong Offer Shares (being 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

As the over-subscription in the Hong Kong Public Offering represents less than 15 times of the number of the Offer Shares initially available for subscription under the Hong Kong Public Offering, no reallocation procedures as described in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus has been applied. The final number of Offer Shares under the Hong Kong Public Offering is 1,900,000 Offer Shares, representing 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 5,793 successful applicants under the Hong Kong Public Offering. A total number of 4,262 applicants have been allotted with one board lot of Offer Shares.

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the section headed “Basis of allocation under the Hong Kong Public Offering” below.

## **INTERNATIONAL OFFERING**

The Offer Shares initially offered under the International Offering were slightly over-subscribed, representing approximately 2.15 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares allocated to the places under the International Offering is 17,100,000 Shares, representing 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total of 194 places under the International Offering. A total of 139 places have been allotted five board lots of Offer Shares or less, representing approximately 71.6% of 194 places under the International Offering. These places have been allotted 18,600 Shares in total, representing approximately 0.1% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

## Cornerstone Investors

Based on the Offer Price of HK\$30.50 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements with the Cornerstone Investors as disclosed in the section headed “Cornerstone Placing” in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investors has now been determined as set out below:

	Number of Offer Shares subscribed for	Approximate % of the Offer Shares initially available under the Global Offering <sup>(1)</sup>	Approximate % of the total issued share capital of the Company immediately following the completion of the Global Offering <sup>(2)</sup>
Sanofi Foreign Participations B.V. (“Sanofi”)	3,860,600	20.32%	0.66%
Harvest International Premium Value (Secondary Market) Fund SPC on behalf of Harvest Great Bay Investment SP (“Harvest”)	5,147,500	27.09%	0.88%
Yangtze River (Hong Kong) Limited (“Yangtze HK”)	1,286,800	6.77%	0.22%
Tasly International Capital Limited (“Tasly”)	1,286,800	6.77%	0.22%
<b>Total</b>	<b><u>11,581,700</u></b>	<b><u>60.96%</u></b>	<b><u>1.97%</u></b>

Notes:

- (1) Assuming that the Over-allotment Option is not exercised.
- (2) Assuming that the Over-allotment Option is not exercised and excluding shares to be issued under the Share Incentive Plans.

An aggregate of 11,581,700 Offer Shares, representing approximately 60.96% of the Offer Shares initially available under the Global Offering (assuming that the Over-allotment Option is not exercised), were placed to Sanofi, Harvest, Yangtze HK and Tasly as Cornerstone Investors. As further described in the section headed “Cornerstone Placing” of the Prospectus, Tasly (the “**Relevant Cornerstone Investor**”) is an affiliate of Tianjin Huaxin Pharmaceutical Venture Capital Partnership (Limited Partnership) (an existing Shareholder, together with Tasly, the “**Participating Investors**”). An aggregate of 1,286,800 Offer Shares, representing approximately 6.77% of the Offer Shares initially available under the Global Offering (assuming that the Over-allotment Option is not exercised) were placed to Tasly. Upon completion of the Global Offering, the Participating Investors shall hold in aggregate 8,944,939 Shares, representing approximately 1.52% of the Company’s issued share capital immediately upon completion of Global Offering (assuming that the Over-allotment Option is not exercised and excluding shares to be issued under the Share Incentive Plans). We have applied to the Stock Exchange for, and the Stock Exchange has granted us, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and consent under paragraph 5(2) of Appendix 6 to the Listing Rules to allow the Relevant Cornerstone Investor to participate in the Global Offering as a cornerstone investor, subject to the following conditions:

- (i) the Participating Investors are interested in less than 5% of the Company’s voting rights before the Listing;
- (ii) the Participating Investors are not and will not be a core connected person of the Company or a close associate of any such core connected person immediately prior to or following completion of the Global Offering and the Listing;
- (iii) the Participating Investors do not have the power to appoint Directors or any other special rights in the Company;
- (iv) the allocation to the Relevant Cornerstone Investor will not affect the Company’s ability to satisfy the minimum public float requirement under Rule 8.08(1) of the Listing Rules; and
- (v) written confirmations pursuant to paragraph 4.20 of the Stock Exchange’s Guidance Letter HKEX-GL85-16 will be provided to the Stock Exchange:
  - (a) the Joint Sponsors shall confirm that, based on (i) their discussions with the Company and the Joint Bookrunners; and (ii) the confirmations to be provided to the Stock Exchange by the Company (the confirmation mentioned in sub-paragraph (b) below) and the Joint Bookrunners, and to the best of their knowledge and belief, they have no reason to believe that the Relevant Cornerstone Investor or its respective close associates received any preferential treatment in the allocation in the International Offering as a cornerstone investor

by virtue of its relationship with the Company other than the preferential treatment of assured entitlement under a cornerstone investment following the principles set out in the Stock Exchange’s Guidance Letter HKEX-GL51-13 (“**GL51-13**”), and details of the allocation will be disclosed in the prospectus and the allotment results announcement of the Company; and

- (b) the Company shall confirm that no preferential treatment has been, nor will be, given to the Relevant Cornerstone Investor or its relevant close associates by virtue of its relationship with the Company other than the preferential treatment of assured entitlement under a cornerstone investment following the principles set out in GL51-13, that the Relevant Cornerstone Investor’s cornerstone investment agreement does not contain any material terms which are more favorable to it than those in other cornerstone investment agreements.

Save for Tasly as disclosed above, to the best knowledge of our Company, each of the Cornerstone Investors (i) is an Independent Third Party, (ii) is independent of other Cornerstone Investors, (iii) is not financed by us, our Directors, chief executive, substantial shareholders, existing Shareholders or any of its subsidiaries or their respective close associates, and (iv) is not accustomed to take instructions from us, our Directors, chief executive, substantial shareholders, existing Shareholders or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their name or otherwise held by them. There are no side arrangements between us and the Cornerstone Investors. Tasly, a close associate of an existing shareholder of the Company, acquainted with the Company during the Pre-IPO Investment; Sanofi acquainted with the Company through business relationship; Yangtze HK acquainted with the Company through the introduction by a business acquaintance within the healthcare industry who is an Independent Third Party; and Harvest became acquainted with the Company through introduction by CMB International Capital Limited. As confirmed by each Cornerstone Investor, their subscription under the Cornerstone Placing would be financed by their own internal financial resources and/or the financial resources of their shareholders.

Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six months following the Listing Date (the “**Lock-up Period**”), dispose of any of the Offer Shares they have purchased pursuant to the relevant Cornerstone Investment Agreement, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries who will be bound by the same obligations of such Cornerstone Investor, including the Lock-up Period restriction.

To the best of the knowledge of the Directors, save as disclosed in this announcement, (i) none of the Offer Shares subscribed for by the placees or the public has been financed by us, our Directors, chief executive, substantial shareholders, existing Shareholders or any of its subsidiaries or their respective close associates and (ii) none of the placees and the

members of the public who or which have subscribed for the Offer Shares is accustomed to take instructions from us, our Directors, chief executive, substantial shareholders, existing Shareholders or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their name or otherwise held by them.

Please refer to the section headed “Cornerstone Placing” in the Prospectus for further details relating to the Cornerstone Investors.

### **Placings of Offer Shares to a close associate of an existing shareholder with consent under paragraph 5(2) of the Placing Guidelines**

Certain Offer Shares were placed to the close associate of certain existing shareholder, details of which are set out below:

<b>Placee</b>	<b>Relationship with the Company</b>	<b>Number of Shares held by Shanghai Runmin and/or Ms. Xie immediately prior to the Global Offering (% of the Company’s issued share capital)</b>	<b>Number of Offer Shares subscribed for by Ms. Xie under the Global Offering (% of total Offer Shares available under the Global Offering)<sup>(1)</sup></b>	<b>Number of Shares held by Shanghai Runmin and/or Ms. Xie immediately following completion of the Global Offering (% of the Company’s issued share capital upon Listing)<sup>(2)</sup></b>
Xie Xiaomei (謝曉梅) (“Ms. Xie”)	Close associate of Shanghai Runmin Information Technology Partnership (Limited Partnership) (上海潤民信息科技合夥企業 (有限合夥)) (“Shanghai Runmin”).  Ms. Xie is the spouse of Gong Xiaodong (宮曉冬) (“Mr. Gong”). Mr. Gong and Ms. Xie directly holds 80% and 20% equity interest in Beijing Jinquan Angel Investment Co., Ltd. (北京錦泉天使投資有限公司), respectively, which in turn is the executive partner and general partner of Shanghai Runmin.	14,573,236 Shares (2.57%)	509,600 Shares (2.68%)	15,082,836 Shares (2.57%)

*Notes:*

- (1) Assuming that the Over-allotment Option is not exercised.
- (2) Assuming that the Over-allotment Option is not exercised and excluding shares to be issued under the Share Incentive Plans.

We have applied to the Stock Exchange for, and the Stock Exchange has granted us, a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and consent under paragraph 5(2) of Appendix 6 to the Listing Rules (the “**Placing Guidelines**”) to permit the Company to allocate Offer Shares in the Global Offering to Ms. Xie Xiaomei (謝曉梅) as placee under the International Offering.

### **Over-allotment Option**

In connection with the Global Offering, we have granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives (for themselves and on behalf of the International Underwriters), at any time from the Listing Date until 30 days after the last day for lodging application under the Hong Kong Public Offering, to require us to allot and issue up to an aggregate of 2,850,000 additional Offer Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover the over-allocations in the International Offering. There has been an over-allocation of 2,850,000 Offer Shares in the International Offering and such over-allocation will be settled using Shares to be borrowed under the Stock Borrowing Agreement between Morgan Stanley & Co International plc, an affiliate of Morgan Stanley Asia Limited, and HaoYuan health Limited. Such borrowed Shares will be covered by, among other methods, exercising the Over-allotment Option in full or in part or by using Shares purchased by the Stabilizing Manager (or through its affiliates or any person acting for it) in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on our website and the website of the Stock Exchange at [www.cloudr.cn](http://www.cloudr.cn) and [www.hkexnews.hk](http://www.hkexnews.hk), respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

## BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the paragraph headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus, valid applications made by the public through the **HK eIPO White Form** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

<b>Number of shares applied for</b>	<b>Number of valid applications</b>	<b>Basis of allocation/ballot</b>	<b>Approximate percentage allotted of the total number of shares applied for</b>
<b>POOL A</b>			
100	5,092	2,546 out of 5,092 applicants to receive 100 shares	50.00%
200	555	386 out of 555 applicants to receive 100 shares	34.77%
300	937	816 out of 937 applicants to receive 100 shares	29.03%
400	185	100 shares	25.00%
500	274	100 shares plus 55 out of 274 applicants to receive an additional 100 shares	24.01%
600	107	100 shares plus 41 out of 107 applicants to receive an additional 100 shares	23.05%
700	55	100 shares plus 30 out of 55 applicants to receive an additional 100 shares	22.08%
800	47	100 shares plus 32 out of 47 applicants to receive an additional 100 shares	21.01%
900	31	100 shares plus 27 out of 31 applicants to receive an additional 100 shares	20.79%
1,000	295	200 shares	20.00%
1,500	556	200 shares plus 298 out of 556 applicants to receive an additional 100 shares	16.91%
2,000	103	200 shares plus 83 out of 103 applicants to receive an additional 100 shares	14.03%
2,500	26	300 shares	12.00%
3,000	61	300 shares plus 28 out of 61 applicants to receive an additional 100 shares	11.53%
3,500	27	300 shares plus 23 out of 27 applicants to receive an additional 100 shares	11.01%



<b>Number of shares applied for</b>	<b>Number of valid applications</b>	<b>Basis of allocation/ballot</b>	<b>Approximate percentage allotted of the total number of shares applied for</b>
4,000	21	400 shares	10.00%
4,500	13	400 shares plus 4 out of 13 applicants to receive an additional 100 shares	9.57%
5,000	48	400 shares plus 24 out of 48 applicants to receive an additional 100 shares	9.00%
6,000	44	500 shares	8.33%
7,000	10	500 shares plus 5 out of 10 applicants to receive an additional 100 shares	7.86%
8,000	9	600 shares	7.50%
9,000	8	600 shares plus 4 out of 8 applicants to receive an additional 100 shares	7.22%
10,000	52	700 shares	7.00%
20,000	19	1,100 shares	5.50%
30,000	13	1,500 shares	5.00%
40,000	5	1,900 shares	4.75%
50,000	7	2,300 shares	4.60%
70,000	4	3,100 shares	4.43%
100,000	7	4,300 shares	4.30%
<b>Total</b>	<b>8,611</b>	<b>Total number of Pool A successful applicants: 5,775</b>	

#### **Pool B**

200,000	9	22,900 shares	11.45%
300,000	1	34,300 shares	11.43%
500,000	2	56,900 shares	11.38%
800,000	3	90,900 shares	11.36%
950,000	3	107,700 shares	11.34%
<b>Total</b>	<b>18</b>	<b>Total number of Pool B successful applicants: 18</b>	

The final number of Offer Shares comprising the Hong Kong Public Offering is 1,900,000 Offer Shares, representing 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

## LOCK-UP UNDERTAKINGS

The Company, almost all existing Shareholders and the Cornerstone Investors have provided lock-up undertakings (the “**Lock-up Undertakings**”) in respect of our Shares. The major terms of the Lock-up Undertakings are set out as follows:

Name	Number of Shares subject to the Lock-up Undertakings after Listing	Percentage of shareholding in the Company subject to the Lock-up Undertakings after Listing <sup>(1)</sup>	Last day of the lock-up period
<b>The Company</b> (subject to lock-up obligations pursuant to the Listing Rules, the Hong Kong Underwriting Agreement and the International Underwriting Agreement)	N/A	N/A	January 6, 2023 <sup>(2)</sup>
<b>Existing Shareholders (other than (i) The Valliance Fund, (ii) SINO CULTURE INTERNATIONAL II L.P., and (iii) China Taiping Life Insurance (Hong Kong) Company Limited)</b> (subject to lock-up obligations pursuant to their respective lock-up undertakings to the Company, the Joint Sponsors and the Joint Representatives)	546,295,421	93.06%	January 6, 2023 <sup>(3)</sup>
<b>Cornerstone Investors</b> (subject to lock-up obligations pursuant to the relevant cornerstone investment agreements)	11,581,700	1.97%	January 6, 2023 <sup>(4)</sup>

*Notes:*

- (1) Assuming that the Over-allotment Option is not exercised and excluding shares to be issued under the Share Incentive Plans.
- (2) The Company may not issue Shares prior to the indicated date except otherwise permitted by the Listing Rules.
- (3) Such existing Shareholders shall not dispose of any of its existing Shares prior to the indicated date.
- (4) Each of the Cornerstone Investors shall not dispose of any of the Offer Shares acquired in the Global Offering prior to the indicated date save for certain limited circumstances as provided under the relevant cornerstone investment agreement.

## RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **HK eIPO White Form** service or through the **CCASS EIPO** service, including the Hong Kong identity card numbers, passport numbers, Hong Kong business registration numbers or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares, successfully applied for, will be made available at the times and dates and in the manner specified below:

- in the announcement to be posted on our website and the website of the Stock Exchange at [www.cloudr.cn](http://www.cloudr.cn) and [www.hkexnews.hk](http://www.hkexnews.hk), respectively, by no later than Tuesday, July 5, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
- from the “IPO Results” function in the **IPO App** or the designated results of allocations website at [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) or [www.tricor.com.hk/ipo/result](http://www.tricor.com.hk/ipo/result) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Tuesday, July 5, 2022 to 12:00 midnight on Monday, July 11, 2022; and
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Tuesday, July 5, 2022 to Friday, July 8, 2022.

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

## SHAREHOLDING CONCENTRATION ANALYSIS

We set out below the analysis of shareholding concentration in the International Offering.

- subscription of Shares held by the top 1, 5, 10 and 25 of the placees out of the International Offer Shares, total Offer Shares and our total issued share capital upon Listing (without taking into account the Shares which may be issued pursuant to the Share Incentive Plans):

Placees	Subscription	Subscription as % of final International Offer Shares (assuming no exercise of the Over-allotment Option)			Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)			% of total Shares upon Listing (assuming the Over-allotment Option is exercised in full)
		Subscription as % of final International Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of final International Offer Shares (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	
Top 1	5,147,500	30.1%	25.8%	27.1%	23.6%	0.9%	0.9%	
Top 5	15,442,300	90.3%	77.4%	81.3%	70.7%	2.6%	2.6%	
Top 10	18,292,800	107.0%	91.7%	96.3%	83.7%	3.1%	3.1%	
Top 25	19,890,300	116.3%	99.7%	104.7%	91.0%	3.4%	3.4%	

- subscription of Shares held by the top 1, 5, 10 and 25 of the Shareholders out of the International Offer Shares, total Offer Shares and our total issued share capital upon Listing (without taking into account the Shares which may be issued pursuant to the Share Incentive Plans):

Shareholders	Subscription	Shareholding	Subscription as % of final International Offer Shares (assuming no exercise of the Over-allotment Option)			Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)			% of total Shares upon Listing (assuming the Over-allotment Option is exercised in full)
			Subscription as % of final International Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of final International Offer Shares (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	
Top 1	-	89,414,780	-	-	-	-	15.2%	15.2%	
Top 5	-	256,842,891	-	-	-	-	43.8%	43.5%	
Top 10	-	372,814,073	-	-	-	-	63.5%	63.2%	
Top 25	5,147,500	510,429,360	30.1%	25.8%	27.1%	23.6%	86.9%	86.5%	